Gallinamide A

Gallinamide A
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
  • O=C1O[C@@]3(C)[C@H](C(=O)N[C@@]13[C@@H](O)[C@@H]2/C=C\CCC2)CCCl
Properties
C31H52N4O7
Molar mass 592.778 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X markN verify (what is checkYX markN ?)

Gallinamide A is potent and selective inhibitor of the human cysteine protease Cathepsin L1 that was first used as a moderate antimalarial agent. Gallinamide A is produced by marine cyanobacteria from Schizothrix species and Symploca sp.[1] which have also shown to have possible anticancer agent, infectious diseases like leishmaniasis, trypanosomiasis and possible uses in Alzheimer's disease, among others.[2]

History

Gallinamide A was first isolated from a Panamanian collection of marine cyanobacteria in 2009 (Schizothrix species) for activity against the malaria causing parasite Plasmodium falciparum.[3] Later, was subsequently and independently isolated by Taori and co-workers from a Floridian Cyanobacteria collection in Key Largo from Symploca sp. and given the name symplostatin 4.[4] Gallinamide A, among other cyanobacteria metabolites such as viridamide A & B, dragonamide E, and almiramide E; are lipodepsipeptides that proved to show anti-infective activities.[3] Gallinamide A was originally isolated with a modest antimalarial activity, which was then proven to be a potent inhibitor of cysteine protease cathepsin L with a IC50 5.0 ug/mL,[2] nonetheless, human cathepsin L is involved in many diseases, gallinamide A was tested in HeLa cervical cancer cells with a IC50 12 mM and in HT-29 colon adenocarcinoma cells with an IC50 of mM.

Mechanism of action

Gallinamide A is a potent and selective irreversible inhibitor of human Cathepsin L1, with a high selectivity towards cysteine cathepsin protease family.[1]

Total synthesis

The first stereoselective synthesis was reported by Conroy and co-workers.[3]

Clinical study

Gallinamide A is a potent inhibitor of cathepsin L with an IC50 value of 17.6 pM. Also, was tested for its antimalarial activity against the W2 chloroquine-resistant strain of the malaria parasite. This compound showed moderate in vitro activity against Plasmodium falciparum (IC50 = 8.4 μM), cytotoxicity to mammalian Vero cells (TC50 = 10.4 μM) and activity against Leishmania donovani of (IC50 = 9.3 μM), but was inactive up to the highest tested concentrations against Trypanasoma cruzi (16.9 μM). No in vivo or human testing has been perform since it is only for research development.[4]

References

  1. ^ a b Joshawna K Nunnery, Emily Mevers, William H Gerwick, Biologically active secondary metabolites from marine cyanobacteria, Current Opinion in Biotechnology, Volume 21, Issue 6, 2010, Pages 787-793, ISSN 0958-1669,
  2. ^ a b Boudreau, Paul D.; Miller, Bailey W.; McCall, Laura-Isobel; Almaliti, Jehad; Reher, Raphael; Hirata, Ken; Le, Thu; Siqueira-Neto, Jair L.; Hook, Vivian; Gerwick, William H. (24 October 2019). "Design of Gallinamide A Analogs as Potent Inhibitors of the Cysteine Proteases Human Cathepsin L and Trypanosoma cruzi Cruzain". Journal of Medicinal Chemistry. 62 (20): 9026–9044. doi:10.1021/acs.jmedchem.9b00294. PMC 7240701. PMID 31539239.
  3. ^ a b c Conroy, Trent; Guo, Jin T.; Elias, Nabiha; Cergol, Katie M.; Gut, Jiri; Legac, Jennifer; Khatoon, Lubna; Liu, Yang; McGowan, Sheena; Rosenthal, Philip J.; Hunt, Nicholas H.; Payne, Richard J. (26 December 2014). "Synthesis of Gallinamide A Analogues as Potent Falcipain Inhibitors and Antimalarials". Journal of Medicinal Chemistry. 57 (24): 10557–10563. doi:10.1021/jm501439w. hdl:2123/22261. PMID 25412465.
  4. ^ a b Miller, Bailey; Friedman, Aaron J.; Choi, Hyukjae; Hogan, James; McCammon, J. Andrew; Hook, Vivian; Gerwick, William H. (24 January 2014). "The Marine Cyanobacterial Metabolite Gallinamide A Is a Potent and Selective Inhibitor of Human Cathepsin L". Journal of Natural Products. 77 (1): 92–99. Bibcode:2014JNAtP..77...92M. doi:10.1021/np400727r. PMC 3932306. PMID 24364476.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.